ADDISON, Texas, July 8, 2014 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR) today announced that it has completed shipments to Serbia, Macedonia, Montenegro and Afghanistan. In addition, the international marketing network has been expanded to include Russia, Greece and the United Arab Emirates.
Commenting on the commercial update, Kerry P. Gray, President and CEO, stated, "This update confirms the great progress the management of Altrazeal GmbH is making expanding our global commercial footprint. In addition, it clearly demonstrates the recognition by commercial partners of the economic benefits that can be derived using Altrazeal®. This validates the potential for Altrazeal® to be marketed in both developed and developing markets. With the recent clinical and pharmacoeconomic data that has been generated in Europe, additional opportunities are being identified both internationally and in the United States."
Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressing. Altrazeal® competes in the advanced wound dressing market which, worldwide, is estimated to be $6.5 billion growing annually at 13%. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous leg ulcers and geriatric wounds.
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the cost of Altrazeal®, ability to market Altrazeal® in developed and developing markets, treatment relative to competitors, recognition of the economic benefits of Altrazeal®, the clinical and economic data supporting Altrazeal® and the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by us with the Securities and Exchange Commission.
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
SOURCE ULURU Inc.